The Cigna Group (CI) posed notable changes on the horizon as it announced its CEO,
David M. Cordani, was going to be succeeded by President & COO,
Brian Evanko - a surprising succession say some investors as per Barclays. This shift has put focus on the firm’s AI execution. CI’s stock has been trading below the industry P/E leading to questioning of whether it is worth retaining. Following recent share price weaknesses, Bernstein upgraded CI with a raised price target.
Capital World Investors,
Magnetar Financial LLC and
MAI Capital Management all boosted their holdings in CI. The firm’s year-end results were positive, anchored on integrated care and pharmacy services, and a Q4 rebound in Health Insurance Provider Stocks. CI’s valuation was evaluated post portfolio changes and
FTC settlement. Yet, CI’s share price fell amidst news of CEO change and regulatory concerns raising questions on its current valuation. CI also received increased price targets from
Truist and
Bernstein, with Deutsche Bank placing a buy recommendation on the health insurance firm.
The Cigna Group CI News Analytics from Tue, 08 Jul 2025 07:00:00 GMT to Sat, 14 Mar 2026 21:27:00 GMT -
Rating -5
- Innovation 0
- Information 5
- Rumor 1
